AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2019
Jan 10, 2019
32312_dirs_2019-01-10_549f3b7d-13fd-46f5-9ef6-bc237a809cdd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01
Reporting Person: Tomasello Shawn (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $49.40 | 2028-07-09 | Ordinary Shares (30000) | Direct | |
| Stock Option (right to buy) | $49.40 | 2028-07-09 | Ordinary Shares (20000) | Direct |
Footnotes
F1: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after July 9, 2018.
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11